Literature DB >> 3066540

Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis.

K Lassoued1, M N Guilly, C Andre, M Paintrand, D Dhumeaux, F Danon, J C Brouet, J C Courvalin.   

Abstract

Fifty sera which gave ring-like nuclear staining in immunofluorescence on rat liver tissue sections were characterized. Using immunoprecipitation and Western blotting we showed that 10 of the sera contained antibodies to 200 kD polypeptide(s) of nuclear envelope. Clinical and biological data were available for nine of the patients. Strikingly, all of these patients suffered from primary biliary cirrhosis with eight of them having anti-mitochondrial antibodies. As no control serum displayed such a reactivity, anti-200 kD polypeptide(s) antibodies can be considered as a new marker specific of a subset of primary biliary cirrhosis, being present even when anti-mitochondrial antibodies are absent. The exact identity of the target remains to be established, since several polypeptides of similar molecular weight have been reported to belong to the nuclear envelope.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3066540      PMCID: PMC1541802     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  The presentation and diagnosis of 100 patients with primary biliary cirrhosis.

Authors:  S Sherlock; P J Scheuer
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

3.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  The complex nature of mitochondrial antibodies and their relation to primary biliary cirrhosis.

Authors:  H Baum; P A Berg
Journal:  Semin Liver Dis       Date:  1981-11       Impact factor: 6.115

Review 6.  Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

7.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

Authors:  W N Burnette
Journal:  Anal Biochem       Date:  1981-04       Impact factor: 3.365

8.  Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients.

Authors:  E Christensen; J Crowe; D Doniach; H Popper; L Ranek; J Rodés; N Tygstrup; R Williams
Journal:  Gastroenterology       Date:  1980-02       Impact factor: 22.682

9.  Nuclei from rat liver: isolation method that combines purity with high yield.

Authors:  G Blobel; V R Potter
Journal:  Science       Date:  1966-12-30       Impact factor: 47.728

10.  Antinuclear autoantibodies specific for lamins. Characterization and clinical significance.

Authors:  K Lassoued; M N Guilly; F Danon; C Andre; D Dhumeaux; J P Clauvel; J C Brouet; M Seligmann; J C Courvalin
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

View more
  12 in total

Review 1.  Primary biliary cirrhosis: nature of autoantigens.

Authors:  M F Bassendine; S J Yeaman
Journal:  Springer Semin Immunopathol       Date:  1990

2.  The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore.

Authors:  J C Courvalin; K Lassoued; E Bartnik; G Blobel; R W Wozniak
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

Review 3.  Autoantigens in primary biliary cirrhosis.

Authors:  D E Jones
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

4.  Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent.

Authors:  C-Y Yang; P S C Leung; G-X Yang; T P Kenny; W Zhang; R Coppel; G L Norman; A A Ansari; I R Mackay; H J Worman; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2012-06       Impact factor: 4.330

5.  Diagnostic value of anti-gp210 antibodies in primary biliary cirrhosis: a case-based review.

Authors:  Florent Valour; Stéphane Durupt; Safia Khenifer; Isabelle Durieu
Journal:  BMJ Case Rep       Date:  2013-06-26

6.  Epstein-barr virus as a trigger of autoimmune liver diseases.

Authors:  Eirini I Rigopoulou; Daniel S Smyk; Claire E Matthews; Charalambos Billinis; Andrew K Burroughs; Marco Lenzi; Dimitrios P Bogdanos
Journal:  Adv Virol       Date:  2012-05-28

7.  Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis.

Authors:  J C Courvalin; K Lassoued; H J Worman; G Blobel
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

Review 8.  Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22.

Authors:  Daniel S Smyk; Maria G Mytilinaiou; Piotr Milkiewicz; Eirini I Rigopoulou; Pietro Invernizzi; Dimitrios P Bogdanos
Journal:  Auto Immun Highlights       Date:  2011-09-07

Review 9.  Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies.

Authors:  Malgorzata Milkiewicz; Llorenç Caballería; Daniel S Smyk; Piotr Milkiewicz
Journal:  Auto Immun Highlights       Date:  2012-10-16

10.  Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210.

Authors:  R E Nickowitz; H J Worman
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.